1620579-54-5

Basic information

• Product Name: 3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzaldehyde
• Synonyms: 3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzaldehyde
• CAS NO: 1620579-54-5
• Molecular Formula: C₁₃H₆F₅NO₂
• Molecular Weight: 303.184256
• Mol File: 1620579-54-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 288.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.465±0.06 g/cm3(Predicted)
• PKA: -0.12±0.20(Predicted)
• CAS DataBase Reference: 3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzaldehyde(1620579-54-5)
• EPA Substance Registry System: 3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzaldehyde(1620579-54-5)

Safety Data

• Hazardous Substances Data: 1620579-54-5(Hazardous Substances Data)

Upstream product

• 170886-13-2 4-hydroxy-2-trifluoromethylpyridine 
• 132123-54-7 3,4,5-trifluorobenzaldehyde 
• 204516-31-4 2-(trifluoromethyl)-4H-pyran-4-one 

Downstream Products

• 1620579-55-6 (3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)phenyl)methanol 
• 1620578-11-1 (S)-7-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy)-1,2-dimethyl-2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one 
• 1620578-97-3 (S)-7-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy)-2-methyl-2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one 
• 1620579-10-3 (R)-7-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy)-2-methyl-2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one 

Relevant articles and documents

Tricyclic pyrimidone compounds, preparation methods thereof, compositions thereof and uses

A tricyclic pyrimidone compound shown in formula (I) or its tautomer, racemic racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, having a structure shown in formula (I), is a brand new Lp-PLA2 inhibitor that can be used to treat neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis.

COMPOUNDS

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.

COMPOUNDS

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.